Intravascular mesenchymal stromal/stem cell therapy product diversification

• Verfasst von: Moll, Guido [VerfasserIn]
• Verfasst von: Bieback, Karen [VerfasserIn]
• Titel: Intravascular mesenchymal stromal/stem cell therapy product diversification
• Titelzusatz: time for new clinical guidelines
• Verf.angabe: Guido Moll, James A. Ankrum, Julian Kamhieh-Milz, Karen Bieback, Olle Ringdén, Hans-Dieter Volk, Sven Geissler, and Petra Reinke
• E-Jahr: 2019
• Jahr: 30 January 2019
• Umfang: 15 S.
• Fussnoten: Gesehen am 26.11.2019
• Titel Quelle: Enthalten in: Trends in molecular medicine
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 2001
• Jahr Quelle: 2019
• Band/Heft Quelle: 25(2019), 2, Seite 149-163
• ISSN Quelle: 1471-499X
• DOI: doi:10.1016/j.molmed.2018.12.006
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: CD142
• Sach-SW: cellular therapy
• Sach-SW: hemocompatibility
• Sach-SW: mesenchymal stromal/stem cell
• Sach-SW: safety and efficacy
• Sach-SW: tissue factor
• Sach-SW: tissue source
• K10plus-PPN: 1677850507

Abstract

Intravascular infusion is the most popular route for therapeutic multipotent mesenchymal stromal/stem cell (MSC) delivery in hundreds of clinical trials. Meta-analysis has demonstrated that bone marrow MSC infusion is safe. It is not clear if this also applies to diverse new cell products derived from other sources, such as adipose and perinatal tissues. Different MSC products display varying levels of highly procoagulant tissue factor (TF) and may adversely trigger the instant blood-mediated inflammatory reaction (IBMIR). Suitable strategies for assessing and controlling hemocompatibility and optimized cell delivery are crucial for the development of safer and more effective MSC therapies.